Lirum Therapeutics (Lirum Therapeutics) Price-to-Tangible-Book : 0.00 (As of Jun. 11, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Price-to-Tangible-Book?

As of today (2024-06-11), Lirum Therapeutics's share price is $0.00. Lirum Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.26. Hence, Lirum Therapeutics's Price to Tangible Book Ratio of today is 0.00.

The historical rank and industry rank for Lirum Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

LRTX's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.79
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Lirum Therapeutics's share price is $0.00. Lirum Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.26. Hence, Lirum Therapeutics's P/B Ratio of today is 0.00.

Lirum Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Lirum Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Price-to-Tangible-Book Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Price-to-Tangible-Book	-	-	-	-	-

Competitive Comparison of Lirum Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Lirum Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lirum Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lirum Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Lirum Therapeutics's Price-to-Tangible-Book falls into.

Lirum Therapeutics Price-to-Tangible-Book Calculation

Lirum Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	0.00	/	0.258
	=	0.00

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Lirum Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines